An Aptinyx Parkinson’s disease drug candidate failed to beat a placebo—the biotech’s third mid-stage failure in the past year. Aptinyx is now terminating a separate PTSD program, cutting costs, and exploring “strategic alternatives.”
An analyst said the news could negatively affect shares of a successor to the company that developed rapastinel - which Allergan bought in 2015 - given that its drugs belong to the same class.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
Just weeks after being acquired by Allergan, the team behind Chicago-based Naurex is launching a new startup: Aptinyx. It'll focus on developing drugs for diseases of the brain and nervous system.